Company news
Adalta Ltd. (ASX:1AD) news
Adalta Ltd. news releases on 6ix. Latest, Oct 4, 2026: EW-001 JDC milestone approvals
Press releases & updates
EW-001 JDC milestone approvals
October 4, 2026
China Representative Office opens
September 30, 2026
US FDA grants EW-001 pre-IND meeting
September 22, 2026
Oribiotech deal validates AdAlta manufacturing strategy
September 17, 2026
BZDS1901 special access scheme launch in China
September 1, 2026
EW-001 IIT study overall survival update
August 9, 2026
2 year survival milestone for EW-001 patient
August 4, 2026
Oktopi AI collaboration for research efficiency
July 1, 2026
Second BZDS1901 milestone paid
June 30, 2026
Regulatory advisors appointed for BZDS1901
May 24, 2026
$2.5m placement
May 4, 2026
BZDS1901 manufacturing agreement
April 28, 2026
Automated cell therapy manufacturing MoU
April 20, 2026
BZDS1901 clinical update
March 31, 2026
AdCella and SHcell hold first JDC meeting
March 26, 2026
New AD-214 patent granted
March 19, 2026
AdCella expands clinical advisory board
March 3, 2026
AdCella Clinical Advisory Board convened
February 25, 2026
Half Yearly Report and Accounts
February 19, 2026
Quarterly Appendix 4C and Activities Report
January 29, 2026
AdCella milestones and regulatory progress
January 20, 2026
Placement raises A$1.2 million
January 12, 2026
CAR-T collaboration agreement
January 1, 2026
$0.78 million FY25 RDTI refund received
December 3, 2025
AGM share consolidation resolution withdrawal
November 6, 2025
Meurs Group Investment Agreement Update
October 27, 2025
NLSC investment balance repaid
October 23, 2025
Letter to Shareholders, Notice of AGM & Proxy Form
October 23, 2025
At market Placement raises additional up to A$1.1 million
October 19, 2025
Placement raises up to A$0.5 million and transaction update
October 12, 2025
Preliminary Final Report
August 26, 2025
Investor Presentation - TechKnow Invest Roadshow
August 18, 2025
Renounceable Rights Issue shortfall placed
June 12, 2025
Rights Issue raises $1.1million
June 2, 2025
Notice of change of exercise price of options
May 28, 2025
Prospectus
May 4, 2025
Renounceable Rights Issue to Raise up to $1.3 million
May 1, 2025
Trading Halt
April 29, 2025
SYNBV invest up to $2m in East to West subsidiary
March 19, 2025
R&D Tax Incentive advance received
March 4, 2025
Investor Presentation
February 6, 2025
East to West cell therapy strategy update
February 5, 2025
AD-214 clinical advisory board
October 9, 2024
FY24 RDTI Refund Received $1.77m
October 3, 2024
Transaction, investment facility update
September 2, 2024
$1.9 million raised from exercise of 1ADOA options
June 2, 2024
Cellular immunotherapy manufacturer secured - Cell Therapies
May 12, 2024
Extension of Victorian Government RDTI Loan Facility
April 28, 2024
Institutional investment to pursue strategic initiatives
April 28, 2024
SYNBV MoU Webinar presentation
April 9, 2024